^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sirtratumab vedotin (ASG-15ME)

    i
    Other names: ASG-15ME, ASG 15ME, ASG 15E
    Company:
    Astellas
    Drug class:
    Microtubule inhibitor, SLITRK6-targeted antibody-drug conjugate
    Related drugs:
    6ms
    Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. (PubMed, Ther Adv Urol)
    These initial studies led to FDA approval of two antibody-drug conjugates, enfortumab vedotin and sacituzumab govitecan...The combination of enfortumab vedotin and pembrolizumab was recently approved for first-line treatment of advanced urothelial carcinoma. Despite the great promise of these novel drugs, robust predictive biomarkers are needed to determine the patients who would maximally benefit. This review surveys the rationale and current state of the evidence for these new drugs and describes future directions actively being explored.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Aidixi (disitamab vedotin) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • sirtratumab vedotin (ASG-15ME)